misetionamide
panavance therap
['gp-2250', 'ovarian']
panavance therapeutics announces positive preclinical data demonstrating gp-2250 single-agent and combination activity for the treatment of ovarian cancer - presented at the american association for cancer research (aacr) annual meeting 2023 gp-2250 s ... 
CEO Of Digital Media Online